ATyr Pharma Faces Investor Suit Over Failed Drug Trial
By Sydney Price · October 10, 2025, 8:14 PM EDT
Rare disease biotech aTyr Pharma Inc. and its CEO have been hit with a proposed shareholder class action accusing them of misleading the public about the efficacy of aTyr's lung disease...
To view the full article, register now.